Teva Pharmaceutical Industries (BSP:T1EV34) Construction In Progress : R$6,992 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Teva Pharmaceutical Industries Construction In Progress?

Teva Pharmaceutical Industries's quarterly construction in progress stayed the same from Jun. 2023 (R$0 Mil) to Sep. 2023 (R$0 Mil) but then increased from Sep. 2023 (R$0 Mil) to Dec. 2023 (R$6,992 Mil).

Teva Pharmaceutical Industries's annual construction in progress increased from Dec. 2021 (R$5,847 Mil) to Dec. 2022 (R$6,289 Mil) and increased from Dec. 2022 (R$6,289 Mil) to Dec. 2023 (R$6,992 Mil).

Teva Pharmaceutical Industries Construction In Progress Historical Data

The historical data trend for Teva Pharmaceutical Industries's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Construction In Progress Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

2,758.22

4,800.01

5,847.17

6,289.24

6,992.02

Teva Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Construction In Progress	Get a 7-Day Free Trial															6,289.24	-	-	-	6,992.02

Teva Pharmaceutical Industries Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Teva Pharmaceutical Industries (BSP:T1EV34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (BSP:T1EV34) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Teva Pharmaceutical Industries (BSP:T1EV34) Headlines

No Headlines